Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | EVP, Corporate Development | February 12, 2020 | February 14, 2020 |
| Organon & Co.OGN · Entity 4115 | Executive VP, Corp. Dev. | March 31, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 12, 2020 · Filed February 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 930.387 |
Ending reported balance
After 2020-02-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-02-12 · Exercise / conversion · Acquired 960 · Balance 1,224.387 Row 2 · 2020-02-12 · Tax withholding · Disposed 294 · Balance 930.387 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-02-12 | Direct | 5,300 |
Reported balance
After 2020-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-12 · Exercise / conversion · Disposed 960 · Balance 5,300 F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-02-12 | Direct | 4,174 |
Reported balance
After 2020-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-12 · Other · Disposed 1,126 · Balance 4,174 F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number of shares that vested. F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2023-02-12 | Direct | 6,030 |
Reported balance
After 2020-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-12 · Grant · Acquired 6,030 · Balance 6,030 F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
Filing footnotes · ownership attribution and instrument terms
F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number of shares that vested.
Organon & Co.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,547.923 |
Ending reported balance
After 2026-03-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-31 · Exercise / conversion · Acquired 11,338 · Balance 68,491.923 Row 2 · 2026-03-31 · Tax withholding · Disposed 3,554 · Balance 64,937.923 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Row 3 · 2026-03-31 · Exercise / conversion · Acquired 6,715 · Balance 71,652.923 Row 4 · 2026-03-31 · Tax withholding · Disposed 2,105 · Balance 69,547.923 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 100,166 |
Reported balance
After 2026-03-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-31 · Grant · Acquired 100,166 · Balance 100,166 F2: On March 31, 2026, the Reporting Person was granted 100,166 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-31 · Exercise / conversion · Disposed 11,338 · Balance 0 F3: Each RSU represents a contingent right to receive one share of Organon common stock. F4: On March 31, 2023, the Reporting Person was granted 34,014 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,432 |
Reported balance
After 2026-03-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-31 · Exercise / conversion · Disposed 6,715 · Balance 13,432 F3: Each RSU represents a contingent right to receive one share of Organon common stock. F5: On March 31, 2025, the Reporting Person was granted 20,147 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
F2: On March 31, 2026, the Reporting Person was granted 100,166 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
F3: Each RSU represents a contingent right to receive one share of Organon common stock.
F4: On March 31, 2023, the Reporting Person was granted 34,014 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
F5: On March 31, 2025, the Reporting Person was granted 20,147 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 6,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · derivative · entry 7 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,432 Underlying: Common Stock · 6,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 20,147 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F5 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 20,147 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 11,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · derivative · entry 6 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,338 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F4 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 34,014 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F4 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 34,014 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 100,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · derivative · entry 5 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,166 Underlying: Common Stock · 100,166 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 100,166 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 100,166 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 100,166 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,105 | $5.70 | $11,998.50 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · nonDerivative · entry 4 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,547.923 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 6,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · nonDerivative · entry 3 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,652.923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 3,554 | $5.70 | $20,257.80 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · nonDerivative · entry 2 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,937.923 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 11,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · nonDerivative · entry 1 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,491.923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:14 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 14,184 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022415 · wk-form4_1774988059.xml · derivative · entry 3 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,185 Underlying: Common Stock · 14,184 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F4 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:14 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 4,446 | $5.84 | $25,964.64 |
DisclosureSEC source: 0001628280-26-022415 · wk-form4_1774988059.xml · nonDerivative · entry 2 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,153.923 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. F2 · balance_after: Includes the addition of 746.463 shares of Organon common stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:14 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 14,184 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022415 · wk-form4_1774988059.xml · nonDerivative · entry 1 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,853.46 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2025 Filed May 7, 2025 12:09 UTC | Organon & Co. OGN · Entity 4115 | PurchaseCommon Stock | 3,500 | $8.24 | $28,828.10 |
DisclosureSEC source: 0001821825-25-000029 · wk-form4_1746634167.xml · nonDerivative · entry 1 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,669.46 Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · derivative · entry 14 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,294 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F8 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F8 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · derivative · entry 13 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,861 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F7 · derivative.exercise_date: On November 7, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F7 · derivative.expiration_date: On November 7, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 11,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · derivative · entry 12 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,338 Underlying: Common Stock · 11,338 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. F6 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 14,184 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · derivative · entry 11 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,369 Underlying: Common Stock · 14,184 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 20,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · derivative · entry 10 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,147 Underlying: Common Stock · 20,147 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 99,009 | $0.00 Strike: $14.89 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · derivative · entry 9 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,009 Underlying: Common Stock · 99,009 shares Expires not disclosed F2 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. F2 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,346 | $14.51 | $19,530.46 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 8 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,169.46 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 7 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,515.46 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,524 | $14.51 | $22,113.24 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 6 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,221.46 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 5 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,745.46 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 3,554 | $14.51 | $51,568.54 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 4 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,884.46 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 11,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 3 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,438.46 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 4,446 | $14.51 | $64,511.46 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 2 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,100.46 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 17:44 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 14,184 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-25-000018 · wk-form4_1743630240.xml · nonDerivative · entry 1 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,546.46 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:36 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005781 · form4.xml · derivative · entry 5 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires 2023-02-12 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:36 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,126 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005781 · form4.xml · derivative · entry 4 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,174 Underlying: Common Stock · 1,126 shares Expires 2022-02-12 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number of shares that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:36 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 960 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005781 · form4.xml · derivative · entry 3 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 960 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:36 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 294 | $331.76 | $97,537.44 |
DisclosureSEC source: 0001127602-20-005781 · form4.xml · nonDerivative · entry 2 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930.387 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:36 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 960 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005781 · form4.xml · nonDerivative · entry 1 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,224.387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2019 Filed Jul 5, 2019 20:51 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 390 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-024060 · form4.xml · derivative · entry 4 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,174 Underlying: Common Stock · 390 shares Expires 2021-07-02 F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| July 02, 2019 Filed Jul 5, 2019 20:51 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 196 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-024060 · form4.xml · derivative · entry 3 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,564 Underlying: Common Stock · 196 shares Expires 2021-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| July 02, 2019 Filed Jul 5, 2019 20:51 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 58 | $236.37 | $13,709.46 |
DisclosureSEC source: 0001127602-19-024060 · form4.xml · nonDerivative · entry 2 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264.387 Read SEC document |
| July 02, 2019 Filed Jul 5, 2019 20:51 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 196 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-024060 · form4.xml · nonDerivative · entry 1 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322.387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 20.653 shares acquired under the Biogen Inc. Employee Stock Purchase Plan on 9/28/2018. F2 · balance_after: Includes 23.683 shares acquired under the Biogen Inc. Employee Stock Purchase Plan on 12/31/2019. F3 · balance_after: Includes 82.051 shares acquired under the Biogen Inc. Employee Stock Purchase Plan on 3/29/2019. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:13 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,260 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006084 · form4.xml · derivative · entry 1 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,260 Underlying: Common Stock · 6,260 shares Expires 2022-02-12 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 20:21 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 1,760 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-022624 · form4.xml · derivative · entry 1 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,760 Underlying: Common Stock · 1,760 shares Expires 2021-07-02 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.